Bruce Brink, DO
Family Medicine · Princeton, INNPI 1902898190
Payments from drug & device makers
Across 345 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AbbVie$1K
- AstraZeneca$722
- Novo Nordisk$437
- Novartis$342
- Pfizer$298
- plus $2K from 32 others
What the payments were for
- Food & beverage$6,586100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 72 | $1,482 |
| AbbVie | 72 | $1,122 |
| AstraZeneca | 26 | $722 |
| Novo Nordisk | 21 | $437 |
| Novartis | 28 | $342 |
| Pfizer | 21 | $298 |
| Johnson & Johnson | 9 | $270 |
| Eisai Inc. | 6 | $248 |
| Lilly USA, LLC | 11 | $194 |
| GSK | 9 | $144 |
| Axsome Therapeutics, Inc. | 8 | $141 |
| Bayer | 6 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $115 |
| Dexcom, Inc. | 2 | $107 |
| Boehringer Ingelheim | 7 | $100 |
| Otsuka America Pharmaceutical, Inc. | 5 | $95 |
| Lundbeck LLC | 5 | $94 |
| Sunovion Pharmaceuticals Inc. | 4 | $72 |
| Teva Pharmaceuticals USA, Inc. | 3 | $56 |
| Medtronic | 1 | $52 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $48 |
| Amarin Pharma, Inc. | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Covis Pharma GmbH | 2 | $26 |
| Insulet Corporation | 1 | $26 |
| Shire North American Group Inc | 1 | $21 |
| Corium, LLC | 2 | $20 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,593 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 403 | $161,830 |
| OzempicSemaglutide | 101 | $131,888 |
| JardianceEmpagliflozin | 136 | $112,651 |
| FarxigaDapagliflozin Propanediol | 72 | $66,328 |
| RexultiBrexpiprazole | 68 | $55,590 |
| NuplazidPimavanserin Tartrate | 16 | $49,556 |
| NuedextaDextromethorphan Hbr/Quinidine | 52 | $30,727 |
| LinzessLinaclotide | 41 | $30,268 |
| TradjentaLinagliptin | 48 | $21,956 |
| GemtesaVibegron | 59 | $21,354 |
| TrulicityDulaglutide | 21 | $20,063 |
| JanuviaSitagliptin Phosphate | 12 | $17,176 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $16,985 |
| MyrbetriqMirabegron | 56 | $16,072 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $13,598 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $298 | $161,830403 claims |
| Boehringer IngelheimJardiance, Tradjenta | $100 | $134,607184 claims |
| Novo NordiskOzempic | $437 | $131,888101 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $722 | $92,118142 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $95 | $55,59068 claims |
| AbbVieLinzess | $1,122 | $30,26841 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $14 | $21,35459 claims |
| Lilly USA, LLCTrulicity | $194 | $20,06321 claims |
| GSKBreo Ellipta, Anoro Ellipta | $144 | $13,36127 claims |
| Johnson & JohnsonXarelto | $270 | $11,76150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Princeton
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.